JP2006520755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006520755A5 JP2006520755A5 JP2006502992A JP2006502992A JP2006520755A5 JP 2006520755 A5 JP2006520755 A5 JP 2006520755A5 JP 2006502992 A JP2006502992 A JP 2006502992A JP 2006502992 A JP2006502992 A JP 2006502992A JP 2006520755 A5 JP2006520755 A5 JP 2006520755A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- hydrogen
- alkoxy
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 63
- 239000001257 hydrogen Substances 0.000 claims 63
- 125000003118 aryl group Chemical group 0.000 claims 54
- 150000002431 hydrogen Chemical group 0.000 claims 48
- 125000001072 heteroaryl group Chemical group 0.000 claims 29
- 125000001188 haloalkyl group Chemical group 0.000 claims 28
- 125000005843 halogen group Chemical group 0.000 claims 25
- 229910052717 sulfur Inorganic materials 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000000623 heterocyclic group Chemical group 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 229910052760 oxygen Inorganic materials 0.000 claims 21
- 229910052799 carbon Inorganic materials 0.000 claims 20
- 125000004104 aryloxy group Chemical group 0.000 claims 17
- -1 cyano , hydroxyl Chemical group 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 14
- 125000004043 oxo group Chemical group O=* 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 14
- 125000004438 haloalkoxy group Chemical group 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 125000001931 aliphatic group Chemical group 0.000 claims 6
- 125000005841 biaryl group Chemical group 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 3
- 150000003857 carboxamides Chemical class 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229940124530 sulfonamide Drugs 0.000 claims 3
- 150000003456 sulfonamides Chemical class 0.000 claims 3
- 150000003536 tetrazoles Chemical class 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- 229940123324 Acyltransferase inhibitor Drugs 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 229940113549 Cholesterol inhibitor Drugs 0.000 claims 1
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 229940122199 Insulin secretagogue Drugs 0.000 claims 1
- 229940122355 Insulin sensitizer Drugs 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 239000002404 acyltransferase inhibitor Substances 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000003028 elevating effect Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44830703P | 2003-02-14 | 2003-02-14 | |
| PCT/US2004/002015 WO2004073606A2 (en) | 2003-02-14 | 2004-02-10 | Sulfonamide derivatives as ppar modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006520755A JP2006520755A (ja) | 2006-09-14 |
| JP2006520755A5 true JP2006520755A5 (https=) | 2007-03-29 |
Family
ID=32908574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006502992A Pending JP2006520755A (ja) | 2003-02-14 | 2004-02-10 | Ｐｐａｒモジュレータとしてのスルホンアミド誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7655641B2 (https=) |
| EP (1) | EP1597248B1 (https=) |
| JP (1) | JP2006520755A (https=) |
| CN (1) | CN1751037A (https=) |
| AT (1) | ATE382043T1 (https=) |
| AU (1) | AU2004212887A1 (https=) |
| BR (1) | BRPI0407180A (https=) |
| CA (1) | CA2512883A1 (https=) |
| DE (1) | DE602004010889T2 (https=) |
| ES (1) | ES2297382T3 (https=) |
| MX (1) | MXPA05008581A (https=) |
| WO (1) | WO2004073606A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517884B2 (en) | 1998-03-30 | 2009-04-14 | Kalypsys Inc. | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
| AU2004291259A1 (en) | 2003-11-05 | 2005-06-02 | F. Hoffmann-La Roche Ag | Heteroaryl derivatives as PPAR activators |
| WO2005105736A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
| ES2352085T3 (es) | 2004-05-05 | 2011-02-15 | High Point Pharmaceuticals, Llc | Nuevos compuestos, su preparación y uso. |
| CA2585172C (en) | 2004-10-29 | 2014-08-12 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as modulators of ppar |
| WO2007005455A2 (en) * | 2005-06-30 | 2007-01-11 | Bayer Cropscience Ag | Improved process for preparing (disubstitutedpropenyl) phenylalkyl substituted heterocycles |
| ATE529404T1 (de) | 2005-06-30 | 2011-11-15 | High Point Pharmaceuticals Llc | Phenoxyessigsäuren als ppar-delta-aktivatoren |
| US7915316B2 (en) * | 2005-08-22 | 2011-03-29 | Allergan, Inc | Sulfonamides |
| CN101273013B (zh) * | 2005-09-27 | 2013-06-12 | 盐野义制药株式会社 | 具有pgd2受体拮抗活性的磺酰胺衍生物 |
| EP2407459A1 (en) | 2005-09-27 | 2012-01-18 | Shionogi & Co., Ltd. | Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity |
| HUE040020T2 (hu) | 2005-10-25 | 2019-02-28 | Kalypsys Inc | PPAR modulátorok sói és eljárások metabolikus betegségek kezelésére |
| BRPI0620468A2 (pt) | 2005-12-22 | 2011-11-08 | Transtech Pharma, Inc. | ácidos fenóxi acéticos como ativadores de ppar delta |
| WO2007101864A2 (en) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
| CA2644333C (en) * | 2006-11-06 | 2014-05-06 | Sagami Chemical Research Center | Reaction reagent for trifluoromethylation |
| WO2008091863A1 (en) | 2007-01-23 | 2008-07-31 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| KR101152659B1 (ko) * | 2009-10-09 | 2012-06-15 | 한국과학기술연구원 | 세로토닌 수용체 길항 작용과 세로토닌 트랜스포터 억제 작용을 동시에 가지는 설폰아마이드 화합물 |
| EP2612669A4 (en) | 2010-08-31 | 2014-05-14 | Snu R&Db Foundation | USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST |
| JP5767458B2 (ja) * | 2010-11-09 | 2015-08-19 | スガイ化学工業株式会社 | ポリオキシエチレン付加カリックスアレーン誘導体の製造方法 |
| CN102336689A (zh) * | 2011-08-29 | 2012-02-01 | 天津市筠凯化工科技有限公司 | 4-氯-3-(三氟甲基)苯磺酰氯的制备及其精制方法 |
| WO2013106238A1 (en) | 2012-01-10 | 2013-07-18 | Eli Lilly And Company | Leukotriene b4 antagonist compound |
| WO2015035171A1 (en) | 2013-09-09 | 2015-03-12 | High Point Pharmaceuticals, Llc | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
| US10188627B2 (en) | 2014-10-08 | 2019-01-29 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| US10103402B2 (en) * | 2015-12-01 | 2018-10-16 | University Of Kentucky Research Foundation | Liquid phenothiazine catholytes for non-aqueous redox flow batteries |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| CN119405633B (zh) * | 2024-11-25 | 2025-12-02 | 浙江大学 | 2,6-dmhq在抗心脏和肝脏缺血再灌注损伤中的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084466A (en) * | 1989-01-31 | 1992-01-28 | Hoffmann-La Roche Inc. | Novel carboxamide pyridine compounds which have useful pharmaceutical utility |
| US5089514A (en) * | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| JPH05125038A (ja) * | 1991-03-07 | 1993-05-21 | Tanabe Seiyaku Co Ltd | フエノキシアルカン酸誘導体及びその製法 |
| JPH05194370A (ja) * | 1992-01-22 | 1993-08-03 | Taisho Pharmaceut Co Ltd | スルホンアミド誘導体 |
| US5232945A (en) * | 1992-07-20 | 1993-08-03 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
| JPH0672867A (ja) * | 1992-08-27 | 1994-03-15 | Tanabe Seiyaku Co Ltd | 抗脂血剤 |
| US6062509A (en) | 1994-12-23 | 2000-05-16 | Hexcel Corporation | Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports |
| US5902726A (en) * | 1994-12-23 | 1999-05-11 | Glaxo Wellcome Inc. | Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma |
| KR19980702372A (ko) * | 1995-02-21 | 1998-07-15 | 구니이 야쓰오 | 글루타민산 수용체 작용약 |
| AU721452B2 (en) | 1996-02-02 | 2000-07-06 | Merck & Co., Inc. | Antidiabetic agents |
| GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| JP4253126B2 (ja) * | 1998-01-29 | 2009-04-08 | アムジェン インコーポレイテッド | Ｐｐａｒ−ガンマ調節剤 |
| ATE451346T1 (de) * | 1998-03-10 | 2009-12-15 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| GB9822473D0 (en) * | 1998-10-16 | 1998-12-09 | Glaxo Group Ltd | Chemical compounds |
| US6248781B1 (en) * | 1998-10-21 | 2001-06-19 | Novo Nordisk A/S | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) |
| RU2219172C2 (ru) | 1999-04-06 | 2003-12-20 | Санкио Компани, Лимитед | α-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ |
| YU72201A (sh) * | 1999-04-28 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | Derivati di-aril kiseline kao ppar receptorski ligandi |
| CA2385798A1 (en) | 1999-06-25 | 2001-01-04 | Michael C. Van Zandt | Substituted phenoxyacetic acids |
| US6417212B1 (en) | 1999-08-27 | 2002-07-09 | Eli Lilly & Company | Modulators of peroxisome proliferator activated receptors |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| WO2001025226A1 (en) * | 1999-10-05 | 2001-04-12 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
| PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
| JP4316787B2 (ja) | 2000-01-11 | 2009-08-19 | 壽製薬株式会社 | エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、 |
| JP2004509084A (ja) | 2000-08-23 | 2004-03-25 | イーライ・リリー・アンド・カンパニー | オキサゾリル−アリールオキシ酢酸誘導体およびそのｐｐａｒアゴニストとしての使用 |
| AU2001284660A1 (en) | 2000-08-23 | 2002-03-04 | Eli Lilly And Company | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| US7071220B2 (en) * | 2000-09-18 | 2006-07-04 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
| EP1357908A4 (en) * | 2001-01-30 | 2009-07-15 | Merck & Co Inc | "ACYLSULFAMIDES FOR THE TREATMENT OF FATIBILITY, DIABETES AND LIPID DISORDERS" |
| JP2004520397A (ja) * | 2001-02-15 | 2004-07-08 | ファイザー・プロダクツ・インク | 増殖性アクチベータ受容体（ｐｐａｒ）化合物 |
| CZ20033309A3 (cs) | 2001-06-07 | 2004-05-12 | Eliálillyáandácompany | Modulátory receptorů aktivovaných peroxizomálními proliferátory }PPARB |
| DE60316780T2 (de) | 2002-02-21 | 2008-07-24 | Eli Lilly And Co., Indianapolis | Modulatoren von peroxisome proliferator-aktivierten rezeptoren |
-
2004
- 2004-02-10 ES ES04709806T patent/ES2297382T3/es not_active Expired - Lifetime
- 2004-02-10 DE DE602004010889T patent/DE602004010889T2/de not_active Expired - Fee Related
- 2004-02-10 EP EP04709806A patent/EP1597248B1/en not_active Expired - Lifetime
- 2004-02-10 JP JP2006502992A patent/JP2006520755A/ja active Pending
- 2004-02-10 AU AU2004212887A patent/AU2004212887A1/en not_active Abandoned
- 2004-02-10 CN CNA2004800042507A patent/CN1751037A/zh active Pending
- 2004-02-10 MX MXPA05008581A patent/MXPA05008581A/es active IP Right Grant
- 2004-02-10 CA CA002512883A patent/CA2512883A1/en not_active Abandoned
- 2004-02-10 US US10/542,579 patent/US7655641B2/en not_active Expired - Fee Related
- 2004-02-10 BR BR0407180-8A patent/BRPI0407180A/pt not_active Application Discontinuation
- 2004-02-10 WO PCT/US2004/002015 patent/WO2004073606A2/en not_active Ceased
- 2004-02-10 AT AT04709806T patent/ATE382043T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006520755A5 (https=) | ||
| US10765676B2 (en) | Trk-inhibiting compound | |
| JP2022506887A5 (https=) | ||
| JP2021176846A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| RU2419624C2 (ru) | Сульфонамидные производные как активаторы гликокиназы, применимые для лечения диабета типа 2 | |
| KR102534262B1 (ko) | 헤테로환형 유도체 및 이의 용도 | |
| JP2007532651A5 (https=) | ||
| IL264982B (en) | Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors | |
| JP2010524932A5 (https=) | ||
| JP2004532266A5 (https=) | ||
| JP2009533410A5 (https=) | ||
| JP2009530281A5 (https=) | ||
| WO2004007472A1 (ja) | Ｃｃｒ４アンタゴニストおよびその医薬用途 | |
| RU2008112184A (ru) | Производное тиазола | |
| RU2005136368A (ru) | Производные пиперазина и их применение для лечения неврологических и психиатрических заболеваний | |
| RU2015141278A (ru) | Новое производное 3-(4-(бензилокси)фенил)гекс-4-иновой кислоты, способ его получения и фармацевтическая композиция для профилактики и лечения метаболического заболевания, включающая его в качестве эффективного ингредиента | |
| JP2006523698A5 (https=) | ||
| JP2004529145A5 (https=) | ||
| JP2004149545A (ja) | Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 | |
| JP2008525400A5 (https=) | ||
| JP2008530242A5 (https=) | ||
| JP2004532267A5 (https=) | ||
| JP2006503056A5 (https=) | ||
| JP2008115166A5 (https=) | ||
| JP2017525734A5 (https=) |